Albert Einstein Cancer Ctr-Med is categorized under Hospitals in Bronx, NY and active since 2010.
Albert Einstein Cancer Ctr-Med was established in 2010, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Hospitals business, which does work in the B2C market, and is classified as a Hospitals, under code number 6211111 by the NAICS.
If you are seeking more information, feel free to contact Meryna Gonzalez, Manager at the company’s single location by writing to 1695 Eastchester Road, Bronx, New York NY 10461 or by phoning (718) 405-8505. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Albert Einstein Cancer Ctr-Med |
| Contact Person: | Meryna Gonzalez, Manager |
| Address: | 1695 Eastchester Road, Bronx, New York 10461 |
| Phone Number: | (718) 405-8505 |
| Website Address: | jacobipeds.org |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Hospitals |
| SIC Code: | 8062 |
| NAICS Code: | 6211111 |
| Share This Business: |
Albert Einstein Cancer Ctr-Med was started in 2010 to provide professional Hospitals under the SIC code 8062 and NAICS code 6211111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Meryna Gonzalez, Manager for inquiries that concern Albert Einstein Cancer Ctr-Med by calling the company number (718) 405-8505, as your correspondence is most welcome. Additionally, the physical location of the single location of Albert Einstein Cancer Ctr-Med can be found at the coordinates 40.846116,-73.844632 as well as the street address 1695 Eastchester Road in Bronx, New York 10461.
For its online presence, you may visit Albert Einstein Cancer Ctr-Med’s website at jacobipeds.org and engage with its social media outlets through on Twitter and on Facebook.